Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

90 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
[Markers for diagnosis, prediction and prognosis of prostate cancer].
Taskén KA, Angelsen A, Svindland A, Eide T, Berge V, Wahlquist R, Karlsen S. Taskén KA, et al. Among authors: berge v. Tidsskr Nor Laegeforen. 2005 Dec 1;125(23):3279-82. Tidsskr Nor Laegeforen. 2005. PMID: 16327854 Free article. Norwegian.
Does preoperative magnetic resonance imaging reduce the rate of positive surgical margins at radical prostatectomy in a randomised clinical trial?
Rud E, Baco E, Klotz D, Rennesund K, Svindland A, Berge V, Lundeby E, Wessel N, Hoff JR, Berg RE, Diep L, Eggesbø HB, Eri LM. Rud E, et al. Among authors: berge v. Eur Urol. 2015 Sep;68(3):487-96. doi: 10.1016/j.eururo.2015.02.039. Epub 2015 Mar 23. Eur Urol. 2015. PMID: 25813692 Free article. Clinical Trial.
Low β₂-adrenergic receptor level may promote development of castration resistant prostate cancer and altered steroid metabolism.
Braadland PR, Grytli HH, Ramberg H, Katz B, Kellman R, Gauthier-Landry L, Fazli L, Krobert KA, Wang W, Levy FO, Bjartell A, Berge V, Rennie PS, Mellgren G, Mælandsmo GM, Svindland A, Barbier O, Taskén KA. Braadland PR, et al. Among authors: berge v. Oncotarget. 2016 Jan 12;7(2):1878-94. doi: 10.18632/oncotarget.6479. Oncotarget. 2016. PMID: 26646591 Free PMC article.
PBX3 is a putative biomarker of aggressive prostate cancer.
Ramberg H, Grytli HH, Nygård S, Wang W, Ögren O, Zhao S, Løvf M, Katz B, Skotheim RI, Bjartell A, Eri LM, Berge V, Svindland A, Taskén KA. Ramberg H, et al. Among authors: berge v. Int J Cancer. 2016 Oct 15;139(8):1810-20. doi: 10.1002/ijc.30220. Epub 2016 Jun 25. Int J Cancer. 2016. PMID: 27273830 Free article.
Molecular Subgroup of Primary Prostate Cancer Presenting with Metastatic Biology.
Walker SM, Knight LA, McCavigan AM, Logan GE, Berge V, Sherif A, Pandha H, Warren AY, Davidson C, Uprichard A, Blayney JK, Price B, Jellema GL, Steele CJ, Svindland A, McDade SS, Eden CG, Foster C, Mills IG, Neal DE, Mason MD, Kay EW, Waugh DJ, Harkin DP, Watson RW, Clarke NW, Kennedy RD. Walker SM, et al. Among authors: berge v. Eur Urol. 2017 Oct;72(4):509-518. doi: 10.1016/j.eururo.2017.03.027. Epub 2017 Apr 10. Eur Urol. 2017. PMID: 28408174 Free article.
Ex vivo metabolic fingerprinting identifies biomarkers predictive of prostate cancer recurrence following radical prostatectomy.
Braadland PR, Giskeødegård G, Sandsmark E, Bertilsson H, Euceda LR, Hansen AF, Guldvik IJ, Selnæs KM, Grytli HH, Katz B, Svindland A, Bathen TF, Eri LM, Nygård S, Berge V, Taskén KA, Tessem MB. Braadland PR, et al. Among authors: berge v. Br J Cancer. 2017 Nov 21;117(11):1656-1664. doi: 10.1038/bjc.2017.346. Epub 2017 Oct 3. Br J Cancer. 2017. PMID: 28972967 Free PMC article.
90 results